Curavatinib refers to lenvatinib, and the treatment of advanced hepatocellular carcinoma some patients can get better results, the patients’ symptoms are reduced and the overall survival time is prolonged. Lenvatinib is an oral multi-targeted targeted drug, which is mainly used in the first-line treatment of advanced hepatocellular carcinoma. Clinical studies have confirmed that clinical symptoms will be reduced and quality of survival will be improved after the use of Lenvatinib, and the survival time of some patients with advanced stage can be more than one year. However, it is generally difficult to completely cure advanced hepatocellular liver cancer. Common side effects after the use of lenvatinib include diarrhea, rash, liver function impairment, bleeding, etc. Therefore, it is necessary to be given guidance on the use of the drug by a professional oncologist.